Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.

J Oncol · 2009 · PMC2677718 · PMID 19424511

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In a phase III study of HER2-positive advanced or metastatic breast cancer refractory to anthracyclines, taxanes, and trastuzumab, lapatinib plus capecitabine showed a significant advantage over capecitabine monotherapy with respect to ORR and PFS with a nonsignificant trend toward longer OS [ 67 ].

also in 5,406 other papers

did not reach statistical significanceno p-value reported

Median TTP was two months longer in the combination arm, but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.